Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 25, 2026.

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

Jing Zhao, Xinyue Liu, Weiming Xia and 2 more

Frontiers in Molecular Neuroscience · 2020 · Review · CC BY

doi:10.3389/fnmol.2020.00137

Abstract

Alzheimer's disease (AD) is the most common type of senile dementia, characterized by neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were devoted to the interference with the production and accumulation of amyloid-β peptide (Aβ), which plays a causal role in the pathogenesis of AD. Aβ is generated from amyloid precursor protein (APP), by consecutive cleavage by β-secretase and γ-secretase. Therefore, β-secretase and γ-secretase inhibition have been the focus for AD drug discovery efforts for amyloid reduction. Here, we review β-secretase inhibitors and γ-secretase inhibitors/modulators, and their efficacies in clinical trials. In addition, we discussed the novel concept of specifically targeting the γ-secretase substrate APP. Targeting amyloidogenic processing of APP is still a fundamentally sound strategy to develop disease-modifying AD therapies and recent advance in γ-secretase/APP complex structure provides new opportunities in designing selective inhibitors/modulators for AD.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Alzheimer’s disease (AD) is a progressive and incurable neurodegenerative disorder, characterized by progressive and irreversible loss of memory. AD is the leading cause of senile dementia. The number of people age 65 and older living with AD’s dementia in the United States is projected to grow from 5.8 million in 2020 to 13.8 million by 2050. Cognitive deficits caused by AD, such as progressive memory loss, difficulty in communication and movement disorder, significantly compromise the patients’ quality of life, leading to hospitalization and eventually death due to complications. AD has been recognized as one of the most difficult medical problems with hefty economic burden. Total medical expenses for Alzheimer’s or other dementias in the United States are projected to be $305 billion in 2020. The cost of AD is likely to skyrocket in the near future, due to rising ageing population, increasing mortality relative to other disease and the absence of a disease-modifying drug. Therefore, there is a major unmet medical need for disease-modifying therapies for AD.

Approved drugs for AD include acetylcholinesterase inhibitors (Aricept®, Exelon®, Razadyne®) and NMDA-antagonist memantine (Namenda®). However, these drugs are not disease-modifying, only improving symptoms without slowing down or stopping AD from progressing. In the last 30 years, a large number of drug candidates have entered clinical development but no new drug for AD has been approved since memantine in 2003. The majority of AD drug discovery focused on inhibiting the amyloid-β peptide (Aβ) production from the amyloidogenic processing of APP.

Amyloid Cascade Hypothesis and Amyloidogenic Processing of APP

In the past 30 years, the amyloid hypothesis has been extensively tested and amyloid has been the most compelling therapeutic target for AD. Despite ongoing debates about this hypothesis in light of recent failures of anti-amyloid-based clinical trials, new evidences continue to emerge to support the idea that an imbalance between production and clearance of Aβ peptides is the initiating event of AD pathogenic processes. Abnormal accumulation of amyloid eventually leads to formation of senile plaques and neurofibrillary tangles, two pathological hallmarks of AD. Aβ aggregates were found to be toxic both in vitro and in vivo. Numerous studies have shown that Aβ aggregates, especially soluble oligomers, impair both synaptic function and structure. Injection of soluble Aβ42 oligomers directly isolated form AD cerebral cortex into healthy rats leads to impaired memory. In addition, accumulation of Aβ oligomers can not only trigger AD-type tau hyperphosphorylation and cause neurotic dystrophy, but also activate neuroinflammation. Apolipoprotein E4, the greatest genetic risk factor for late-onset AD, impairs Aβ clearance and promotes Aβ accumulation in the brain. Along with tau, Aβ might be transmissible through the Aβ contaminants in cadaver-derived human growth hormone for the treatment of Creutzfeldt-Jakob disease. From human genetics, dominant mutations causing early-onset familial AD reside either in APP or presenilin (catalytic sub-unit of γ-secretase), which alter the proteolytic processing of APP in ways either elevating the Aβ42/Aβ40 ratio or increasing the self-aggregation propensity of resultant Aβ peptides. Duplication of the APP gene in Down’s syndrome leads to Aβ deposits in the teens, and almost invariably leads to AD at an early age. Interestingly, three DS patients with partial trisomy that excludes the APP gene did not develop dementia. The human genetics of DS strikingly demonstrates that increasing Aβ dosage (APP duplication) causes dementia, while normalized Aβ dosage in DS (partial trisomy without APP duplication) prevents dementia (albeit the sample size = 3 is low), affirming that amyloid reduction is a fundamentally sound strategy for disease-modifying treatment of AD. The failures of anti-amyloid clinical trials in recent years can be attributed to giving the therapy too late to the patients, poor clinical trial design, heterogeneity of the trial patient population etc.

Aβ is a small peptide generated by proteolytic processing of APP (Figure 1A), a type-I transmembrane protein with a large extracellular domain. APP is transported to the plasma membrane through the endoplasmic reticulum -Golgi secretory pathway. The majority of APP is processed via the non-amyloidogenic pathway at the plasma membrane (Figure 1A). In the non-amyloidogenic pathway, APP is cleaved by α-secretase within the Aβ domain between Lys16 and Leu17, producing a soluble N-terminal fragment (APPs α) and a membrane-bound C-terminal fragment, C83, which can be further cleaved by γ-secretases and generates a soluble extracellular p3 peptide, thus precluding the formation of intact Aβ (Figure 1A;;; ). Unlike the non-amyloidogenic pathway, APP is internalized and delivered to endosomes in the amyloidogenic pathway. During amyloidogenic APP processing, APP is cleaved by β-secretase (BACE1, β-site APP-cleaving enzyme 1), generating a soluble N-terminal fragment (APPsβ) and a membrane-bound C-terminal fragment (C99). Within the membrane, C99 is subsequently cleaved by an enzymatic complex known as γ-secretase, releasing a cytoplasmic polypeptide termed AICD (APP intracellular domain) at the luminal side and Aβ peptides at the other side of the membrane. AICD is transferred to the nucleus, where it functions as a transcriptional factor, whereas the Aβ peptides are secreted into the extracellular space when the endosome recycles to cell surface. γ-Secretase cleaves APP at variable sites within the transmembrane domain, generating Aβ peptides ranging in length from 38 to 43 residues. Among different Aβ species, Aβ42 and Aβ43 are highly self-aggregating, while Aβ40 and shorter peptides are relatively benign. Aβ42 and Aβ40 are the two common Aβ species in the human brain and the increased Aβ42/Aβ40 ratio is a common biochemical feature in the early-onset familial AD (FAD) caused by mutations in APP and presenilin. Aβ42 aggregates rapidly into neurotoxic oligomers, leading to fibrils and plaques. It has been proposed that Aβ oligomers are more toxic than fibrils, therefore it may play a more important role than amyloid plaque in AD progression. Aberrant process of APP by β-secretase and γ-secretase may result in imbalance between production and clearance of Aβ peptides, leading to toxic oligomers, fibrils and senile plaques. Interestingly, pathogenic mutations in presenilin were found to destabilize γ-secretase-APP interactions and thus enhance the production of longer Aβ peptides. These finding points to enhancing the stability of γ-secretase-Aβn complex as a potential therapeutic approach for AD.

Drug Discovery Targeting Amyloidogenic Processing of APP

Interference with the amyloidogenic processing of APP has been a major strategy to modulate Aβ production. As two crucial enzymes catalyzing the intramembrane proteolysis of APP, β-secretase and γ-secretase have been the most prominent targets for AD drug discovery. In the past two decades, numerous β-secretase inhibitors and γ-secretase inhibitors/modulators were discovered to inhibit or modulate the amyloidogenic processing of APP, either causing the reduced production of total Aβn or shifting the production of Aβ to shorter and more benign Aβ species (Figure 1B).

β-Secretase

β-secretase, also named as BACE1 (β-site APP-cleaving enzyme 1), was identified in 1999 as an APP-cleaving aspartyl protease. BACE1 is the principal neuronal protease for generating C99 from APP, which leads to subsequent Aβ generation by γ-secretase. Importantly, BACE1 shedding of APP is a prerequisite for γ-secretase cleavage within the transmembrane domain of APP for Aβ production. Secretion of Aβ peptides is abolished in cultures of BACE1-deficient embryonic cortical neurons. Naturally, BACE1 inhibition has been a widely pursued therapeutic target for amyloid reduction.

BACE1 is a type-I membrane protein with 501 amino acid residues related to the pepsin family. It is localized within acidic subcellular compartments of the secretory pathway, primarily the Golgi apparatus and endosomes. As shown in Figure 2A. BACE1 has an N-terminal signal sequence (residues 1–21), a pro-peptide domain (residues 22–45), a large luminal catalytic domain (residues 46-451), a single transmembrane domain (residues 452-483), and a short cytoplasmic domain (residues 484-501). In addition, BACE1 has several N-linked glycosylation sites and six cysteine residues that form three intramolecular disulfide bonds, C216-C420, C278-C443, and C330-C380. The N-terminal signal sequence and pro-peptide domain were removed post-translationally, so the mature BACE1 sequence begins at residue Glu46. In the luminal catalytic domain for the β-site cleavage of APP, BACE1 contains two motifs, DTGS (residues 93–96) and DSGT (residues 289–292), which contain the two highly conserved catalytic aspartates. The crystal structure of the catalytic domain (residues 56-446) of BACE1 with an inhibitor was first published by Hong et al. in 2000 (PDB code: 1FKN). Like other aspartic proteases, the substrate binding cleft was located between the N- and C-terminal lobes of BACE1, together with a β-hairpin loop which forms the flap region. The flap opens to allow the substrate to enter and then closes down on the substrate during catalysis and reopens to release the hydrolyzed products. As shown in Figure 2B, the two conserved aspartate, D93 and D289, are located at the groove between the N- and C-terminal lobes, partially covered by the “flap” (residues 130-135). A later substrate-free (apo) structure of BACE1 (PDB code: 1W50) showed a water molecule located between D93 and D289, which is likely involved in nucleophilic attack for peptide hydrolysis and important binding site for inhibitors.

BACE1 cleavage is highly specific and cleaves APP only at the β-secretase sites of Asp1 and Glu11 of Aβ. As expected, BACE1 cleaves the Swedish APP mutant 10 to 100-fold more efficiently than wild-type APP. BACE1 appeared to be an ideal target for drug discovery since its complete inhibition should shut down the amyloidogenic APP processing.

Drug Discovery Targeting BACE1

The first generation of BACE1 inhibitors are peptidomimetic transition-state analogs, which were designed to be accommodated within the substrate-binding cleft of BACE1. In 2000, Hong et al. developed an 8-residue peptide OM99-2 utilizing the template of the β-cleavage site of Swedish APP, where the scissile peptide bond was replaced by a Leu-Ala hydroxyethylene transition-state isostere (Figure 3B; ). The crystal structure of BACE1 and OM99-2 complex (Figure 3A) provided coveted molecular insight into the ligand/enzyme interaction and significantly advanced the development of BACE1 inhibitors. Catalytic aspartates D93 and D289 (see Figure 3A, in green) are located at the center of the substrate binding pocket. There are four hydrogen bonds between the catalytic aspartates and the transition state isostere hydroxyl, and ten hydrogen bonds between the binding cleft and flap to OM99-2 backbone. As shown in Figure 3A, the “flap” (in yellow) closes over the top of the cleft upon the binding of the inhibitor. Futher investigation led to the design of inhibitor OM00-3 by the replacement of the P2’ Ala in OM99-2 with a Val, which achived a five-fold enhancement of inhibitory potency. Additional peptidomimetic inhibitors were developed, including KMI-008, KMI-420, and KMI-429 by Kiso’s group, GSK188909, and compound 11, etc. However, the big molecular size precludes the application of peptidomimetic BACE1 inhibitors in vivo, due to their short half-life, deficiency in crossing the BBB, and low oral availability. Therefore, later generations of BACE1 inhibitors are mostly non-peptidic small molecules.

High-throughput screening (HTS) and fragment-based drug discovery (FBDD) are two major methods employed to explore non-peptidyl small molecule BACE1 inhibitors. In contrast to traditional HTS, which uses libraries of drug-like compounds (typically 300–500 Da), FBDD screens libraries of small fragments (typically < 300 Da), allowing more thorough exploration of the chemical space and the identification of weakly binding chemical fragments. Small fragment hits can then be linked or extended into unique multi-fragment scaffold. Screening of 8000 fragments by Lilly Research Laboratories produced two promising fragment hits, amino-benzothiazine and amino-thiadiazine. Evolution of the fragment based on crystal structure produced compound LY2811376 [(S)-4-(2,4-difluoro-5-pyrimidin-5-yl-phenyl)-4-methyl-5,6-dihydro- 4H-[1,3]thiazin-2-ylamine]. LY2811376 was the first orally available, non-peptidic small-molecule BACE1 inhibitor, showing satisfactory pharmacokinetic and pharmacodynamic properties in preclinical animal models and in humans. The chemical structure of LY2811376 and its complex with BACE1 were shown in Figure 4. LY2811376 binds to the active site of BACE1 and forms an optimal H-bonds network with the catalytic aspartates. Despite the encouraging results in preclinical animal models, LY2811376 shows toxicity in long-term studies. Other fragment-based compounds, including AZD3839 from Astra-Zeneca and NB-360 from Novartis, also showed great potential in reducing brain Aβ levels in preclinical studies.

BACE1 Inhibitors in Clinical Trials

BACE1 inhibitors effectively reduced brain and CSF Aβ levels in both animal studies and human clinical trials. In the past two decades, many potent BACE inhibitors have been developed, but only a small portion entered the clinical trials. Selectivity over other aspartic protease (BACE2, pepsin, renin, cathepsin D, and cathepsin E) and blood-brain barrier (BBB) permeability are major hurdles. The first Phase I clinical trial on a BACE1 inhibitor, CTS-21166, was conducted by CoMentis in 2008. CTS-21166 passes BBB, with high oral bio-availability and selectivity of BACE1 over other proteases. Results from clinical studies indicated a dose-dependent reduction of plasma Aβ for an extended period of time, with up to 80% inhibition at the highest dosage. Merck conducted phase I clinical trial on their inhibitor MK-8931 (Verubecestat) in 2012, which is well-tolerated and demonstrates a profound (up to 94%) reduction in CSF Aβ. MK-8931 is the first BACE1 inhibitor to advance to phase II/III clinical trial in patients with mild to moderate AD. It was discontinued in 2017 (Table 1), due to a lack of clinical benefit in cognition. Subsequent phase III clinical trials of MK-8931 in patients with prodromal AD was also discontinued in 2018, because it was deemed unlikely to exhibit a positive benefit/risk ratio. Several other promising BACE1 inhibitors in late state clinical trials also reported disappointing results, including LY2886721 (Eli Lilly), AZD3839 (AstraZeneca), atabecestat (JNJ-54,861,911, Janssen), and lanabecestat (AZD3293, LY3314814, AstraZeneca and Eli Lilly) (Table 1).

γ-Secretase

γ-secretase is a membrane protein complex composed of four essential subunits, with presenilin-1 (PS1) or presenilin-2 (PS2) as the catalytic subunit, nicastrin (Nct), anterior pharynx-defective 1 (Aph-1), and presenilin enhancer 2 (Pen-2). PS1 undergoes autocleavage through its endopeptidase activity to produce a N-terminal fragment (NTF) and a C-terminal fragment (CTF), each of which contributes a conserved catalytic aspartate, D257 and D385, respectively (Figure 5A). Nct is believed to play a role in substrate recognition and its initial docking. Aph-1 stabilizes the complex and Pen-2 is required for maturation of γ-secretase. γ-secretase cleaves type I transmembrane proteins and has more than 90 reported substrates, of which APP and Notch are the most well-characterized. After the cleavage of APP by BACE1, a C-terminal 99-residue fragment of APP (C99) is generated and subsequently cleaved by γ-secretase. The initial cleavage of γ-secretase produces a 48-residue (Aβ48) or 49-redidue (Aβ49) amyloid peptide, while at the same time the intracellular domains (AICD) are liberated into the cytoplasm (Figure 5B;; ). Subsequent cleavage of Aβ49 by the C-terminal peptidase activity of γ-secretase leads to the generation of Aβ46, Aβ43, and Aβ40, while cleavage of Aβ48 results in Aβ45, Aβ42, and Aβ38. Among Aβ peptides with different lengths, Aβ42 and Aβ43 are most prone to aggregation, while Aβ40 and shorter peptides are relatively benign.

Drug Discovery Targeting γ-Secretase

γ-Secretase cleaves within APP transmembrane domain (APPTM) of C99 to release Aβ, which aggregates to form neurotoxic oligomers and fibrils. Thus, γ-secretase is an obvious drug target for reducing amyloid load. Efforts have been devoted to develop γ-secretase targeting compounds, γ-secretase inhibitors (GSIs) and later γ-secretase modulators (GSMs).

Early studies on γ-secretase targeting compounds have shown an increase of the levels of substrates C99 and C83, and a reduction of the levels of the γ-secretase cleavage products Aβ and p3 in APP-transfected cells. Those compounds were named as GSIs, among which dipeptide aldehydes (such as MG-132 and MDL-28170) were firstly reported. At the same time, substrate-based GSIs were designed, and these compounds show pharmacological effects through occupying the binding site of APP on γ-secretase. The substrate-based GSIs (Figure 6) includes: (1) transition-state analog inhibitor of aspartyl proteases, such as hydroxyethylene L-685,458, which was identified to target PS1 NTF and CTF; (2) helical peptide, which was found to directly bind to the PS1 NTF/CTF interface; (3) Chemically modified compounds based on hits from high-throughput screening, such as DAPT, for which PS1 was identified as the direct target. The complex structure of presenilin homolog PSH bound to a hydroxyethylene derivative L-682,679 was shown in Figure 7. PSH is composed of 9 transmembrane helices (TMs). L-682,679 was found to bind in the cleft surrounded by TMs 2, 6, 7, 8, and 9. The two catalytic aspartates D162 and D220 were separated by the phenol group in the amide end of L-682679.

Additional non-peptidyl GSIs were developed, e.g., modification of DAPT led to a much more potent compound LY-411,575, which was further modified to be LY-450,139 (semagacestat, Table 2), a compound that was advanced to phase III clinical trials. However, the phase III clinical trial revealed severe gastrointestinal toxicity and skin cancer, which were probably due to impairment of Notch signaling.

To avoid the toxicity of GSIs, extensive efforts have been devoted toward selective γ-secretase inhibitors/γ-secretase modulators (GSMs). Some GSMs interact with γ-secretase through the allosteric binding site, and therefore do not interfere with the normal γ-secretase processing of other physiological substrates, such as Notch (called “Notch-sparing GSMs”). The first generation of GSMs is a subset of non-steroidal anti-inflammatory agents (NSAIDs), including ibuprofen, sulindac and indomethacin. These NSAIDs interact with PS at the luminal side and increase the distance between the N- and C- termini of PS, thus direct the cleavage sites toward Aβ38 instead of Aβ42, without altering total Aβ production. The second generation of GSMs include NSAID-derived carboxylic acid analogs and non-NSAID GSMs. The second-generation GSMs have better pharmacokinetic properties, and several of them entered clinical trials, including CHF 5074, EVP-0962, and PF-06648671 (Table 2). Natural products were also screened and characterized for their GSM activities, such as dihydroergocristine (DHEC), curcumin, and luteolin. However, the mechanism of how GSMs shift Aβ production is poorly understood, partially because the complexity of the structure of γ-secretase. γ-Secretase contains 4 subunits and at least 18 transmembrane domains, structural information on this high molecular weight complex is limited until recently. Moreover, the binding sites of GSMs are still not understood. GSMs fenofibrate and tarenflurbil were initially reported to modulate γ-secretase cleavage by binding to the substrate APP, but the specificity of this binding is questionable. Other GSMs have been reported to bind presenilin.

γ-Secretase Inhibitors/Modulators in Clinical Trials

The most potent GSI semagacestat (LY450139) failed in Phase III clinical trials with more than 2600 patients from 31 countries, due to worsening cognition and increased risk of skin cancer in test patients comparing to placebo group. The side effects are likely due to the impaired Notch signaling. Focus was then shifted toward “Notch-sparing” GSMs, which shift the Aβ production to shorter and benign peptides without affecting the total Aβ production. However, avagacestat (BMS-708163), which was claimed to be a Notch-sparing GSI, also failed in a Phase II clinical trial (Table 2) with similar side effects to those found with semagacestat. Later a lack of Notch selectivity was reported for avagacestat, which may contribute to the failure of clinical trial. Two more GSMs entered clinical trials. EVP-0962, entered phase II clinical trial in 2012 but no results have ever been reported. NIC5-15, a naturally occurring sugar alcohol found in plants and fruits, also entered phase II clinical trial without follow-up studies.

Discussion

All clinical trials of BACE1 inhibitors and GSIs/GSMs failed, raising the question about causal role of Aβ in AD pathogenesis, and the validity of amyloid cascade hypothesis in general. However, the amyloid hypothesis refers to a continuum of pathological processes at different stages of disease lasting 15–20 years before symptoms appear. It is widely accepted that amyloid biomarkers (detected by reduced Aβ42 in cerebrospinal fluid (CSF) and/or positive brain amyloid PET imaging) represent the earliest evidence of AD neuropathologic change currently detectable in humans. A causative role of Aβ in AD pathogenesis is supported by strong evidences, including genetic of FAD and Down’s syndrome, toxicity of Aβ aggregates, Aβ activation of neuron inflammation and Aβ potentiation of tau pathology. Very recently, increased Aβ42/40 ratio was shown to drive tau pathology in 3-dimensional human AD neural cell culture models. These studies support the causal upstream role for Aβ in the pathogenesis of AD.

Reducing Aβ42 by modulating β- or γ-secretase activity may inhibit subsequent neurodegenerative changes in the brain. It is clear that Aβ alone is not sufficient for cognitive dysfunction, but it may play a crucial role in potentiating downstream tauopathy and neuroinflammation, converting a cognitively unimpaired preclinical AD subject to a patient with MCI and finally with dementia. With recent advances in ultra-sensitive quantification of pathological proteins in human plasma samples, levels of phosphorylated Tau protein (pTau181) were used to distinguish plasma samples from AD vs. control subjects. For the first time, both Tau and pTau181 can be measured in plasma to predict brain Tau load and neurodegeneration, for monitoring the efficacy of β- or γ-secretase inhibitors/modulators in clinical trials. Existing β-/γ-secretase inhibitors/modulators can then be tested in sub-cohorts selected by AT(N) biomarker.

One plausible explanation for negative clinical results is that BACE1 inhibitors and GSIs/GSMs were given too late, during the irreversible phase of the disease (MCI/prodromal AD, mild-to-moderate AD), and patients need to be treated at earlier stage of AD to prevent neurodegeneration. The phase III trial of BACE1 inhibitor verubecestat by Merck in patients with prodromal AD (MCI) was discontinued in 2018, similar to the phase II/III trial of atabecestat by Janssen.

In addition, side effects and toxicity account for a number of failed trials, such as the inhibition of Notch signaling by GSIs. Recent studies on BACE1 knockout mice suggested that BACE1 inhibitors may disrupt the axonal organization in the hippocampus, and impair synaptic plasticity, leading to defects in learning and memory. Inhibition of γ-secretase cleavage can lead to the accumulation of C99 fragment, which was correlated to the acceleration of early neurodegenerative process in AD.

An obstacle for the development of selective GSMs is the lack of information about the structural characteristics of γ-secretase-substrate complex. Recent cryo-EM structure of γ-secretase bound to the C83 fragment and Notch substrate started to fill this crucial knowledge gap. An α-helical to β-strand transition was observed at the C-terminal of APPTM, forming an anti-parallel, intermolecular β-sheet with two induced β-strands from presenilin (Figure 8). The unwinding of C-terminal transmembrane helix exposes the initial ε-cleavage sites (T48, L49) to interact with γ-secretase. These are in agreement with earlier Raman and NMR spectroscopic studies carried out on APPTM and PSHs in solution, which showed that substrate binding is coupled with helical unwinding to prime the substrate for peptide bond hydrolysis.

This unwinding model of the substrate in γ-secretase-APP interaction suggests that targeting APP, especially the C-terminal of APPTM, could be a new strategy in selective amyloid reduction. A substrate-specific inhibitor is not expected to affect the γ-secretase cleavage of other physiological substrates, the assembly of the γ-secretase complex, or any presenilin function, thereby sparing the side effects associated with broad-spectrum γ-secretase inhibitors. A novel compound C1 was found to interact with the C-terminal juxtamembrane lysines of APP and inhibit the γ-secretase production of Aβ both in vitro and in cell. This study provides the first in vitro evidence that targeting the C-terminal juxtamembrane lysines is sufficient for reducing Aβ production.

Besides cleavage by the well-known α-, β-, and γ-secretases, APP can be alternatively cleaved by meprin-β, legumain, rhomboid-like protein-4 (RHBDL4), caspases, η-secretase (MT-MMPs) at different sites, resulting in different APP fragments (reviewed by ). These emerging proteinases in APP metabolism opened more possibilities for the intervention of amyloidogenic APP processing in AD. For example, cleavage of APP by meprin-β can generate a N-terminally truncated Aβ (Aβ2–X), which is more prone to aggregation than Aβ40; while the inhibitor of meprin-β, fetuin-A, was reduced in CSF of AD patients, indicating a potentially pathogenic role of enhanced meprin-β activity in AD. Further investigations are needed to link the new proteinases to AD pathogenesis, which will offer novel insights and more molecular targets in AD drug discovery.

AD is a complex disease and therefore drugs with a single molecular target may not be sufficient for reversing the progression of AD. Thus, multi-target molecules able to inhibit both APP processing and tau pathology, or neuroinflammation etc., may be a promising approach for the treatment of AD. Emerging multi-targeted molecules are developed based on natural products and their derivatives, such as curcumin, berberine, and epigallocatechin gallate (EGCG). Multiple AD-related clinical trials were carried out for EGCG, which is a polyphenolic flavonoid extracted from green tea. EGCG has been proposed to not only inhibit Aβ misfolding and tau aggregation in vitro but also increase α-secretase cleavage of APP and improve inflammatory in APP/PS1 transgenic mouse models. While the outcome of clinical trials on EGCG is currently inconclusive, more trials are ongoing and it represents an intriguing multi-target strategy in AD treatment.

Summary

Drug discovery targeting Aβ-producing enzymes is one of the most important strategies to develop disease modifying therapeutics for AD. Exploration of “Notch-sparing” GSMs and inhibitors targeting the substrate APP are two promising future directions. Beyond obvious significance in AD drug discovery, investigation of the γ-secretase and BACE inhibitors will not only provide chemical probes to study fundamental enzymatic mechanisms, but also help settling the debates on whether Aβ is indeed a molecular driver in AD pathogenesis.

Author Contributions

JZ and CW conceived and wrote the manuscript. XL, WX, and YZ edited the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 166

  1. 1.

    Ahmed R. Vanschouwen B. Jafari N. Ni X. Ortega J. Melacini G. (2017 ). Molecular mechanism for the (-)-Epigallocatechin gallate-induced toxic to nontoxic remodeling of Aβ oligomers. J. Am. Chem. Soc. 139 13720–13734.

    Not in our library10.1021/jacs.7b05012

  2. 2.

    Ahn J. E. Carrieri C. Dela Cruz F. Fullerton T. Hajos-Korcsok E. He P. (2020 ). Pharmacokinetic and pharmacodynamic effects of a γ-secretase modulator, PF-06648671, on CSF amyloid-β peptides in randomized Phase I studies. Clin. Pharmacol. Ther. 107 211–220.

    Not in our library10.1002/cpt.1570

  3. 3.

    Ahn J. E. Liu R. Trapa P. Wood K. M. Hajos-Korcsok E. Fullerton T. (2017 ). Pharmacokinetic/Pharmacodynamic (Pk/Pd) effects of Pf-06648671, a novel gamma secretase modulator (GSM), following single and multiple dose administration in healthy volunteers. Alzheimer’s Dement. 13:601

    Not in our library10.1016/j.jalz.2017.07.244

  4. 4.

    Albala B. Kaplow J. M. Lai R. Matijevic M. Aluri J. Satlin A. (2012 ). CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609. Alzheimer’s Dement. 8:S743

    Not in our library10.1016/j.jalz.2013.08.023

  5. 5.

    Alzheimer’s_Association (2020 ). Alzheimer’s Association 2020 Facts and Figures Report. Available online at: https://www.alz.org/alzheimers-dementia/facts-figures (accessed July 24, 2020).

    Not in our library

  6. 6.

    Anderson J. P. Esch F. S. Keim P. S. Sambamurti K. Lieberburg I. Robakis N. K. (1991 ). Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci. Lett. 128 126–128.

    Not in our library10.1016/0304-3940(91)90775-o

  7. 7.

    Asai M. Hattori C. Iwata N. Saido T. C. Sasagawa N. Szabó B. (2006 ). The novel β-secretase inhibitor KMI-429 reduces amyloid β peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem. 96 533–540.

    Not in our library10.1111/j.1471-4159.2005.03576.x

  8. 8.
    Sampling the conformational space of the catalytic subunit of human γ-secretase · 2015
    No notice
  9. 9.

    Barthet G. Dunys J. Shao Z. Xuan Z. Ren Y. Xu J. (2013 ). Presenilin mediates neuroprotective functions of ephrinB and brain-derived neurotrophic factor and regulates ligand-induced internalization and metabolism of EphB2 and TrkB receptors. Neurobiol. Aging 34 499–510.

    Not in our library10.1016/j.neurobiolaging.2012.02.024

  10. 10.

    Bateman R. J. Siemers E. R. Mawuenyega K. G. Wen G. Browning K. R. Sigurdson W. C. (2009 ). A γ -secretase inhibitor decreases amyloid-β production in the central nervous system. Ann. Neurol. 66 48–54.

    Not in our library10.1002/ana.21623

  11. 11.

    Beel A. J. Barrett P. Schnier P. D. Hitchcock S. A. Bagal D. Sanders C. R. (2009 ). Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein. Biochemistry 48 11837–11839.

    Not in our library10.1021/bi901839d

  12. 12.

    Beher D. Clarke E. E. Wrigley J. D. J. Martin A. C. L. Nadin A. Churcher I. (2004 ). Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site: evidence for an allosteric mechanism. J. Biol. Chem. 279 43419–43426.

    Not in our library10.1074/jbc.m404937200

  13. 13.

    Benjannet S. Elagoz A. Wickham L. Mamarbachi M. Munzer J. S. Basak A. (2001 ). Post-translational processing of β-secretase (β -amyloid-converting enzyme) and its ectodomain shedding: the pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-β production. J. Biol. Chem. 276 10879–10887.

    Not in our library10.1074/jbc.m009899200

  14. 14.

    Bennett B. D. Denis P. Haniu M. Teplow D. B. Kahn S. Louis J. C. (2000 ). A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer’s β-secretase. J. Biol. Chem. 275 37712–37717.

    Not in our library10.1074/jbc.m005339200

  15. 15.

    Bernier F. Sato Y. Matijevic M. Desmond H. McGrath S. Burns L. (2013 ). Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimer’s Dement. 9:886

    Not in our library10.1016/j.jalz.2013.08.244

  16. 16.

    Berridge M. J. (2010 ). Calcium hypothesis of Alzheimer’s disease. Pflugers Arch. Eur. J. Physiol. 459 441–449.

    Not in our library10.1007/s00424-009-0736-1

  17. 17.

    Brown M. C. Abdine A. Chavez J. Schaffner A. Torres-Arancivia C. Lada B. (2018 ). Unwinding of the substrate transmembrane helix in intramembrane proteolysis. Biophys. J. 114 1579–1589.

    Not in our library10.1016/j.bpj.2018.01.043

  18. 18.

    Bu G. (2009 ). Apolipoprotein e and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10 333–344.

    Not in our library10.1038/nrn2620

  19. 19.

    Burdick D. Soreghan B. Kwon M. Kosmoski J. Knauer M. Henschen A. (1992 ). Assembly and aggregation properties of synthetic Alzheimer’s A4/β amyloid peptide analogs. J. Biol. Chem. 267 546–554.

    Not in our library

  20. 20.

    Cai H. Wang Y. McCarthy D. Wen H. Borchelt D. R. Price D. L. (2001 ). BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4 233–234.

    Not in our library10.1038/85064

  21. 21.

    Carter D. B. Dunn E. McKinley D. D. Stratman N. C. Boyle T. P. Kuiper S. L. (2001 ). Human apolipoprotein E4 accelerates β-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 50 468–475.

    Not in our library10.1002/ana.1134

  22. 22.

    Cebers G. Alexander R. C. Haeberlein S. B. Han D. Goldwater R. Ereshefsky L. (2017 ). AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease. J. Alzheimer’s Dis. 55 1039–1053.

    Not in our library10.3233/jad-160701

  23. 23.

    Chen W. Gamache E. Rosenman D. J. Xie J. Lopez M. M. Li Y. M. (2014 ). Familial Alzheimer’s mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site. Nat. Commun. 5:3037.

    Not in our library10.1038/ncomms4037

  24. 24.

    Chévez-Gutiérrez L. Bammens L. Benilova I. Vandersteen A. Benurwar M. Borgers M. (2012 ). The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31 2261–2274.

    Not in our library10.1038/emboj.2012.79

  25. 25.

    Clemente N. Abdine A. Ubarretxena-Belandia I. Wang C. (2018 ). Coupled transmembrane substrate docking and helical unwinding in intramembrane proteolysis of amyloid precursor Protein. Sci. Rep. 8:12411.

    Not in our library10.1038/s41598-018-30015-6

  26. 26.

    Coric V. Salloway S. Van Dyck C. H. Dubois B. Andreasen N. Brody M. (2015 ). Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 72 1324–1333.

    Not in our library10.1001/jamaneurol.2015.0607

  27. 27.

    Creemers J. W. M. Dominguez D. I. Plets E. Serneels L. Taylor N. A. Multhaup G. (2001 ). Processing of β-secretase by furin and other members of the proprotein convertase family. J. Biol. Chem. 276 4211–4217.

    Not in our library10.1074/jbc.m006947200

  28. 28.

    Crump C. J. Castro S. V. Wang F. Pozdnyakov N. Ballard T. E. Sisodia S. S. (2012 ). BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry 51 7209–7211.

    Not in our library10.1021/bi301137h

  29. 29.

    Crump C. J. Fish B. A. Castro S. V. Chau D. M. Gertsik N. Ahn K. (2011 ). Piperidine acetic acid based γ-secretase modulators directly bind to presenilin-1. ACS Chem. Neurosci. 2 705–710.

    Not in our library10.1021/cn200098p

  30. 30.

    Dang S. Wu S. Wang J. Li H. Huang M. He W. (2015 ). Cleavage of amyloid precursor protein by an archaeal presenilin homologue PSH. Proc. Natl. Acad. Sci. U.S.A. 112 3344–3349.

    Not in our library10.1073/pnas.1502150112

  31. 31.

    Das C. Berezovska O. Diehl T. S. Genet C. Buldyrev I. Tsai J. Y. (2003 ). Designed helical peptides inhibit an intramembrane protease. J. Am. Chem. Soc. 125 11794–11795.

    Not in our library10.1021/ja037131v

  32. 32.

    De Jonghe C. (2001 ). Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10 1665–1671.

    Not in our library10.1093/hmg/10.16.1665

  33. 33.

    De Strooper B. (2003 ). Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38 9–12.

    Not in our library10.1109/tasl.2012.2197612

  34. 34.

    De Strooper B. Saftig P. Craessaerts K. Vanderstichele H. Guhde G. Annaert W. (1998 ). Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391 387–390.

    Not in our library10.1038/34910

  35. 35.

    Dean R. A. Farlow M. R. Galvin J. E. Peskind E. R. Quinn J. F. (2008 ). Phase 2 safety trial targeting amyloid NL production with a γ-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65 1031–1038.

    Not in our library10.1001/archneur.65.8.1031

  36. 36.

    Di Martino R. M. C. De Simone A. Andrisano V. Bisignano P. Bisi A. Gobbi S. (2016 ). Versatility of the curcumin scaffold: discovery of potent and balanced dual BACE-1 and GSK-3β inhibitors. J. Med. Chem. 59 531–544.

    Not in our library10.1021/acs.jmedchem.5b00894

  37. 37.

    Donohue M. C. Jacqmin-Gadda H. Le Goff M. Thomas R. G. Raman R. Gamst A. C. (2014 ). Estimating long-term multivariate progression from short-term data. Alzheimer’s Dement. 10 S400–S410.

    Not in our library10.1016/j.jalz.2013.10.003

  38. 38.

    Doran E. Small G. W. Lott I. T. Kim R. Barrio J. R. Keator D. (2016 ). Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: the role of APP. J. Alzheimer’s Dis. 56 459–470.

    Not in our library10.3233/jad-160836

  39. 39.

    Dorner-Ciossek C. Hobson S. Fuchs K. Sauer A. Bauer M. Morales-Ramos A. (2015 ). Pharmacological characterization of the new bace1 inhibitor bi 1181181. Alzheimer’s Dement. 11:477

    Not in our library10.1016/j.jalz.2015.06.529

  40. 40.

    Dovey H. F. John V. Anderson J. P. Chen L. Z. De Saint Andrieu P. Fang L. Y. (2001 ). Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76 173–181.

    Not in our library10.1046/j.1471-4159.2001.00012.x

  41. 41.

    Duyckaerts C. Sazdovitch V. Ando K. Seilhean D. Privat N. Yilmaz Z. (2018 ). Neuropathology of iatrogenic Creutzfeldt–Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology. Acta Neuropathol. 135 201–212.

    Not in our library10.1007/s00401-017-1791-x

  42. 42.

    Egan M. F. Kost J. Tariot P. N. Aisen P. S. Cummings J. L. Vellas B. (2018 ). Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 378 1691–1703.

    Not in our library10.1056/nejmoa1706441

  43. 43.

    Eketjäll S. Janson J. Kaspersson K. Bogstedt A. Jeppsson F. Fälting J. (2016 ). AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow Off-rate kinetics. J. Alzheimer’s Dis. 50 1109–1123.

    Not in our library10.3233/jad-150834

  44. 44.

    Eng J. A. Frosch M. P. Choi K. Rebeck G. W. Greenberg S. M. (2004 ). Clinical manifestations of cerebral amyloid angiopathy – related inflammation. Ann. Neurol. 55 250–256.

    Not in our library10.1002/ana.10810

  45. 45.

    Erlanson D. A. (2012 ). Introduction to fragment-based drug discovery. Top. Curr. Chem. 317 1–32.

    Not in our library10.1007/128-2011-180

  46. 46.

    Ettcheto M. Cano A. Manzine P. R. Busquets O. Verdaguer E. Castro-Torres R. D. (2020 ). Epigallocatechin-3-Gallate (EGCG) improves cognitive deficits aggravated by an obesogenic diet through modulation of unfolded protein response in APPswe/PS1dE9 Mice. Mol. Neurobiol. 57 1814–1827.

    Not in our library10.1007/s12035-019-01849-6

  47. 47.

    Fairbanks M. Leone J. Emmons T. Drong R. Slightom J. Winterrowd G. (1999 ). Purification and cloning of amyloid precursor protein β-secretase from human brian. Nature 705 537–540.

    Not in our library10.1038/990114

  48. 48.

    Firth I. E. Tools M. H. (2010b ). Single oral doses of the novel BACE inhibitor BI 1181181 significantly reduce concentrations of cerebrospinal fluid amyloid-beta peptides in healthy subjects. JALZ 11:740

    Not in our library10.1016/j.jalz.2015.06.1655

  49. 49.

    Firth I. E. Tools M. H. (2010a ). Pharmacokinetics, pharmacodynamics, and safety of the novel bace inhibitor BI1181181 after oral administration of single ascending doses in healthy subjects. JALZ 11 740–741.

    Not in our library10.1016/j.jalz.2015.06.1656

  50. 50.

    Forman M. Tseng J. Palcza J. Leempoels J. Ramael S. Krishna G. (2012 ). The novel BACE inhibitor MK-8931 dramatically lowers CSF Abeta peptides in healthy subjects: results from a rising single dose study. Neurology 78:PL02.004-PL02.004

    Not in our library10.1212/wnl.78.1_meetingabstracts.pl02.004

  51. 51.

    Franceschi M. Casula D. Bottini G. Giardino L. Scarpini E. Norris D. (2013 ). CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo- controlled study. Curr. Alzheimer Res. 10 742–753.

    Not in our library10.2174/13892037113149990144

  52. 52.

    Gabrielle S. (2008 ). Keystone Drug News: coMentis BACE Inhibitor Debuts. Available online at: http://www.alzforum.org/new/detail.asp?id=1790 (accessed April 5, 2018).

    Not in our library

  53. 53.

    García-González L. Pilat D. Baranger K. Rivera S. (2019 ). Emerging alternative proteinases in APP metabolism and alzheimer’s disease pathogenesis: a focus on MT1-MMP and MT5-MMP. Front. Aging Neurosci. 11:244.

    Not in our library10.3389/fnagi.2019.00244

  54. 54.

    Ghosh A. K. Osswald H. L. (2014 ). BACE1 (β-Secretase) inhibitors for the treatment of Alzheimer’s disease arun. Chem. Soc. Rev. 43 6765–6813.

    Not in our library10.1039/c3cs60460h.bace1

  55. 55.

    Ghosh A. K. Shin D. Downs D. Koelsch G. Lin X. Ermolieff J. (2000 ). Design of potent inhibitors for human brain memapsin 2 (β-secretase) [1]. J. Am. Chem. Soc. 122 3522–3523.

    Not in our library10.1021/ja000300g

  56. 56.

    Golde T. E. Estus S. Younkin L. H. Selkoe D. J. Steven G. Golde T. E. (1992 ). Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255 728–730.

    Not in our library10.1126/science.1738847

  57. 57.

    Goozee K. G. Shah T. M. Sohrabi H. R. Rainey-Smith S. R. Brown B. Verdile G. (2016 ). Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease. Br. J. Nutr. 115 449–465.

    Not in our library10.1017/s0007114515004687

  58. 58.

    Guéroux M. Fleau C. Slozeck M. Laguerre M. Pianet I. (2017 ). Epigallocatechin 3-Gallate as an inhibitor of Tau phosphorylation and aggregation: a molecular and structural insight. J. Prev. Alzheimer’s Dis. 4 218–225.

    Not in our library10.14283/jpad.2017.35

  59. 59.

    Haapasalo A. Kovacs D. M. (2011 ). The many substrates of presenilin/γ-secretase. J. Alzheimer’s Dis. 25 3–28.

    Not in our library10.3233/jad-2011-101065.the

  60. 60.

    Hall A. Elliott R. L. Giblin G. M. P. Hussain I. Musgrave J. Naylor A. (2010 ). Piperidine-derived γ-secretase modulators. Bioorgan. Med. Chem. Lett. 20 1306–1311.

    Not in our library10.1016/j.bmcl.2009.08.072

  61. 61.

    Hansen M. M. Jarmer D. J. Arslantas E. Debaillie A. C. Frederick A. L. Harding M. (2015 ). Synthesis of BACE inhibitor LY2886721. Part II. isoxazolidines as precursors to chiral aminothiazines, selective peptide coupling, and a controlled reactive crystallization. Organ. Process Res. Dev. 19:150828123638003

    Not in our library10.1021/op500327t

  62. 62.

    Head E. Powell D. Gold B. T. Schmitt F. A. (2012 ). Alzheimer’s disease in down syndrome. Eur. J. Neurodegener. Dis. 1 353–364.

    Not in our library

  63. 63.

    Henstridge C. M. Hyman B. T. Spires-Jones T. L. (2019 ). Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 20 94–108.

    Not in our library10.1038/s41583-018-0113-1

  64. 64.

    Higaki J. Quon D. Zhong Z. Cordell B. (1995 ). Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14 651–659.

    Not in our library10.1016/0896-6273(95)90322-4

  65. 65.

    Higaki J. N. Chakravarty S. Bryant C. M. Cowart L. R. Harden P. Scardina J. M. (1999 ). A combinatorial approach to the identification of dipeptide aldehyde inhibitors of β-amyloid production. J. Med. Chem. 42 3889–3898.

    Not in our library10.1021/jm990009f

  66. 66.

    Hong L. Koelsch G. Lin X. Wu S. Terzyan S. Ghosh A. K. (2000 ). Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290 150–153.

    Not in our library10.1126/science.290.5489.150

  67. 67.

    Hong L. Turner R. T. Koelsch G. Shin D. Ghosh A. K. Tang J. (2002 ). Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00-3. Biochemistry 41 10963–10967.

    Not in our library10.1021/bi026232n

  68. 68.

    Huang X. Zhou W. Liu X. Li H. Sun G. Mandal M. (2012 ). Synthesis and SAR studies of fused oxadiazines as γ-secretase modulators for treatment of Alzheimer’s disease. ACS Med. Chem. Lett. 3 931–935.

    Not in our library10.1021/ml300209g

  69. 69.

    Hussain I. Hawkins J. Harrison D. Hille C. Wayne G. Cutler L. (2007 ). Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo. J. Neurochem. 100 802–809.

    Not in our library10.1111/j.1471-4159.2006.04260.x

  70. 70.

    Hussain I. Powell D. Howlett D. R. Tew D. G. Meek T. D. Chapman C. (1999 ). Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell. Neurosci. 14 419–427.

    Not in our library10.1006/mcne.1999.0811

  71. 71.

    Imbimbo B. P. Hutter-Paier B. Villetti G. Facchinetti F. Cenacchi V. Volta R. (2009 ). CHF5074, a novel γ-secretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer’s disease. Br. J. Pharmacol. 156 982–993.

    Not in our library10.1111/j.1476-5381.2008.00097.x

  72. 72.

    Inhibitor B. Hypopigmentation L. Neill B. T. O. Beck E. M. Butler C. R. Nolan C. E. (2018 ). Design and synthesis of clinical candidate PF-06751979: a potent, brain penetrant, β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor lacking hypopigmentation. J. Med. Chem. 61 4476–4504.

    Not in our library10.1021/acs.jmedchem.8b00246

  73. 73.

    Inhibitor B. Part L. Y. Asymmetric I. A. Kolis S. P. Hansen M. M. Arslantas E. (2015 ). Synthesis of BACE inhibitor LY2886721. Part I. An asymmetric nitrone cycloaddition strategy. Org. Process Res. Dev. 19 1203–1213.

    Not in our library10.1021/op500351q

  74. 74.

    Iserloh U. Pan J. Stamford A. W. Kennedy M. E. Zhang Q. Zhang L. (2008 ). Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorganic Med. Chem. Lett. 18 418–422.

    Not in our library10.1016/j.bmcl.2007.10.053

  75. 75.

    Jacobs H. I. L. Hedden T. Schultz A. P. Sepulcre J. Perea R. D. Amariglio R. E. (2018 ). Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat. Neurosci. 21 424–431.

    Not in our library10.1038/s41593-018-0070-z

  76. 76.

    Janelidze S. Mattsson N. Palmqvist S. Smith R. Beach T. G. Serrano G. E. (2020 ). Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, and longitudinal progression to Alzheimer’s dementia. Nat. Med 26 379–386.

    Not in our library10.1038/s41591-020-0755-1

  77. 77.

    Jeppsson F. Eketjäll S. Janson J. Karlström S. Gustavsson S. Olsson L. L. (2012 ). Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of alzheimer disease. J. Biol. Chem. 287 41245–41257.

    Not in our library10.1074/jbc.m112.409110

  78. 78.

    Jin M. Shepardson N. Yang T. Chen G. Walsh D. Selkoe D. J. (2011 ). Soluble amyloid -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108 5819–5824.

    Not in our library10.1073/pnas.1017033108

  79. 79.

    Jurisch-Yaksi N. Sannerud R. Annaert W. (2013 ). A fast growing spectrum of biological functions of γ-secretase in development and disease. Biochim. Biophys. Acta Biomembr. 1828 2815–2827.

    Not in our library10.1016/j.bbamem.2013.04.016

  80. 80.

    Kennedy M. E. Stamford A. W. Chen X. Cox K. Cumming J. N. Dockendorf M. F. (2016 ). The BACE1 inhibitor verubecestat (MK-8931) reduces CNS b-Amyloid in animal models and in Alzheimer’s disease patients. Sci. Transl. Med. 8:363ra150.

    Not in our library10.1126/scitranslmed.aad9704

  81. 81.

    Kieburtz K. He F. Sun X. Thomas R. G. Ph D. Aisen P. S. (2013 ). A Phase 3 trial of semagacestat for treatment of Alzheimer’s disease. 369 341–350.

    Not in our library10.1056/nejmoa1210951

  82. 82.

    Kimura T. Shuto D. Hamada Y. Igawa N. Kasai S. Liu P. (2005 ). Design and synthesis of highly active Alzheimer’s β-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorganic Med. Chem. Lett. 15 211–215.

    Not in our library10.1016/j.bmcl.2004.09.090

  83. 83.

    Klafki H. W. Abramowski D. Swoboda R. Paganetti P. A. Staufenbiel M. (1996 ). The carboxyl termini of β-amyloid peptides 1-40 and 1-42 are generated by distinct γ-secretase activities. J. Biol. Chem. 271 28655–28659.

    Not in our library10.1074/jbc.271.45.28655

  84. 84.

    Kokubo H. Kayed R. Glabe C. G. Yamaguchi H. (2005 ). Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer’s disease brain. Brain Res. 1031 222–228.

    Not in our library10.1016/j.brainres.2004.10.041

  85. 85.

    Korbel J. O. Tirosh-Wagner T. Urban A. E. Chen X.-N. Kasowski M. Dai L. (2009 ). The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc. Natl. Acad. Sci. U.S.A. 106 12031–12036.

    Not in our library10.1073/pnas.0813248106

  86. 86.

    Kornilova A. Y. Bihel F. Das C. Wolfe M. S. (2005 ). The initial substrate-binding site of γ-secretase is located on presenilin near the active site. Proc. Natl. Acad. Sci. U.S.A. 102 3230–3235.

    Not in our library10.1073/pnas.0407640102

  87. 87.

    Kukar T. L. Ladd T. B. Bann M. A. Fraering P. C. Narlawar R. Maharvi G. M. (2008 ). Substrate-targeting γ-secretase modulators. Nature 453 925–929.

    Not in our library10.1038/nature07055

  88. 88.
    Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease · 2020
    No notice
  89. 89.

    Lai R. Y. Darpo B. Dayal S. Hall N. Chang M.-K. Albala B. (2017 ). Elenbecestat, a novel oral bace inhibitor, has no clinically meaningful effect on Qtc interval up to a supratherapeutic dose of 200 Mg. Alzheimer’s Dement. 13 250–251.

    Not in our library10.1016/j.jalz.2017.06.110

  90. 90.

    Lanzillotta A. Sarnico I. Benarese M. Branca C. Baiguera C. Hutter-Paier B. (2010 ). The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated Tau in a transgenic mouse model of Alzheimer’s disease. J. Mol. Neurosci. 45 22–31.

    Not in our library10.1007/s12031-010-9482-2

  91. 91.

    Lauritzen I. Bécot A. Bourgeois A. Pardossi-Piquard R. Biferi M. G. Barkats M. (2019a ). Targeting γ-secretase triggers the selective enrichment of oligomeric APP-CTFs in brain extracellular vesicles from Alzheimer cell and mouse models. Transl. Neurodegener. 8:35.

    Not in our library10.1186/s40035-019-0176-6

  92. 92.

    Lauritzen I. Pardossi-Piquard R. Bauer C. Brigham E. Abraham J. D. Ranaldi S. (2012 ). The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 32 16243–16255.

    Not in our library10.1523/jneurosci.2775-12.2012

  93. 93.

    Lauritzen I. Pardossi-Piquard R. Bourgeois A. Bécot A. Checler F. (2019b ). Does intraneuronal accumulation of carboxyl-terminal fragments of the amyloid precursor protein trigger early neurotoxicity in Alzheimer’s Disease? Curr. Alzheimer Res. 16 453–457.

    Not in our library10.2174/1567205016666190325092841

  94. 94.

    Lei X. Yu J. Niu Q. Liu J. Fraering P. C. Wu F. (2015 ). The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides. Sci. Rep. 5:16541.

    Not in our library10.1038/srep16541

  95. 95.

    Lejeune J. Gautier M. Turpin R. (1959 ). Study of the somatic chromosomes of nine mongoloid children. C. R. Hebd. Seances Acad. Sci. 248 1721–1722.

    Not in our library

  96. 96.

    Lin X. Koelsch G. Wu S. Downs D. Dashti A. Tang J. (2000 ). Human aspartic protease memapsin 2 cleaves the beta -secretase site of beta -amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 97 1456–1460.

    Not in our library10.1073/pnas.97.4.1456

  97. 97.

    Lleó A. Berezovska O. Herl L. Raju S. Deng A. Bacskai B. J. (2004 ). Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation. Nat. Med. 10 1065–1066.

    Not in our library10.1038/nm1112

  98. 98.

    Lombardo S. Chiacchiaretta M. Tarr A. Kim W. H. Cao T. Sigal G. (2019 ). BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Sci. Rep. 9:19877.

    Not in our library10.1038/s41598-019-56329-7

  99. 99.

    Lynch S. Y. Kaplow J. Zhao J. Dhadda S. Luthman J. Albala B. (2018 ). Elenbecestat, E2609, a bace inhibitor: results from a Phase-2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer’S disease. Alzheimer’s Dement. 14:1623

    Not in our library10.1016/j.jalz.2018.07.213

  100. 100.

    Martenyi F. Lowe S. Dean R. A. Monk S. A. Gonzales C. R. Friedrich S. (2010 ). Central and peripheral pharmacokinetic and pharmacodynamic effects of the & beta;-site APP cleavage enzyme (BACE1) inhibitor LY2811376 In humans. Alzheimer’s Dement. 6:e48

    Not in our library10.1016/j.jalz.2010.08.148

  101. 101.

    May P. C. Boggs L. N. Yang Z. Lindstrom T. Calligaro D. Citron M. (2010 ). Central and peripheral pharmacodynamic effects of BACE1 inhibition following oral administration of LY2811376 to PDAPP mice and beagle dog. Alzheimer’s Dement. 6 S590–S591.

    Not in our library10.1016/j.jalz.2010.05.2010

  102. 102.

    May P. C. Dean R. A. Lowe S. L. Martenyi F. Sheehan S. M. Boggs L. N. (2011 ). Robust central reduction of amyloid- in humans with an orally available, non-peptidic -secretase inhibitor. J. Neurosci. 31 16507–16516.

    Not in our library10.1523/jneurosci.3647-11.2011

  103. 103.

    May P. C. Willis B. A. Lowe S. L. Dean R. A. Monk S. A. Cocke P. J. (2015 ). The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J. Neurosci. 35 1199–1210.

    Not in our library10.1523/jneurosci.4129-14.2015

  104. 104.

    Mckinzie D. L. May P. C. Boggs L. N. Yang Z. Brier R. A. Monk S. A. (2016 ). Nonclinical pharmacological characterization of The BACE1 inhibitor LY3202626. Alzheimer’s Dement. 12 432–433.

    Not in our library10.1016/j.jalz.2016.06.828

  105. 105.

    Merck (2018 ). Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer’s Disease. Available online at: https://investors.merck.com/news/press-release-details/2018/Merck-Announces-Discontinuation-of-APECS-Study-Evaluating-Verubecestat-MK-8931-for-the-Treatment-of-People-with-Prodromal-Alzheimers-Disease/default.aspx (accessed February 13, 2018).

    Not in our library

  106. 106.

    Morohashi Y. Kan T. Tominari Y. Fuwa H. Okamura Y. Watanabe N. (2006 ). C-terminal fragment of presenilin is the molecular target of a dipeptidic γ-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L- alanyl]-S-phenylglycine t-butyl ester). J. Biol. Chem. 281 14670–14676.

    Not in our library10.1074/jbc.m513012200

  107. 107.

    Neumann U. Rueeger H. MacHauer R. Veenstra S. J. Lueoend R. M. Tintelnot-Blomley M. (2015 ). A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Mol. Neurodegener. 10 1–15.

    Not in our library10.1186/s13024-015-0033-8

  108. 108.
    The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease · 2018
    No notice
  109. 109.

    Obregon D. F. Rezai-Zadeh K. Bai Y. Sun N. Hou H. Ehrhart J. (2006 ). ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate- induced α-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 281 16419–16427.

    Not in our library10.1074/jbc.m600617200

  110. 110.

    Ohki Y. Higo T. Uemura K. Shimada N. Osawa S. Berezovska O. (2011 ). Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J. 30 4815–4824.

    Not in our library10.1038/emboj.2011.372

  111. 111.

    Ou-Yang M. H. Kurz J. E. Nomura T. Popovic J. Rajapaksha T. W. Dong H. (2018 ). Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Sci. Transl. Med. 10:eaao5620.

    Not in our library10.1126/scitranslmed.aao5620

  112. 112.

    Park J. Wetzel I. Marriott I. Dréau D. D’Avanzo C. Kim D. Y. (2018 ). A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease. Nat. Neurosci. 21 941–951.

    Not in our library10.1038/s41593-018-0175-4

  113. 113.

    Patel S. Vuillard L. Cleasby A. Murray C. W. Yon J. (2004 ). Apo and inhibitor complex structures of BACE (β-secretase). J. Mol. Biol. 343 407–416.

    Not in our library10.1016/j.jmb.2004.08.018

  114. 114.

    Puchades M. Hansson S. F. Nilsson C. L. Andreasen N. Blennow K. Davidsson P. (2003 ). Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease. Mol. Brain Res. 118 140–146.

    Not in our library10.1016/j.molbrainres.2003.08.005

  115. 115.

    Qiu R. Liu R. He P. Wills A. Tankisheva E. Alvey C. (2017 ). Tolerability, and pharmacokinetic and pharmacodynamic effects of PF-06751979, a potent and selective oral BACE1 inhibitor: results from Phase1 single and multiple ascending dose studies in healthy young and older volunteers. Alzheimer’s Dement. J. Alzheimer’s Assoc. 13 575–576.

    Not in our library10.1016/j.jalz.2017.07.196

  116. 116.

    Qiu R. Liu R. Wills A. He P. Leurent C. Hajos-korcsok E. (2016 ). PF-06648671-A novel gamma secretase modulator: safety, tolerability, pharmacokinetics, and effects on plasma amyloid-β Levels following single oral ascending doses in healthy volunteers. Alzheimer’s Dement. 12 611–612.

    Not in our library10.1016/j.jalz.2016.06.1213

  117. 117.

    Rogers K. Felsenstein K. M. Hrdlicka L. Tu Z. Albayya F. Lee W. (2012 ). Modulation of γ -secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol. Neurodegen. 7:61.

    Not in our library10.1186/1750-1326-7-61

  118. 118.

    Rowe C. C. Ellis K. A. Rimajova M. Bourgeat P. Pike K. E. Jones G. (2010 ). Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol. Aging 31 1275–1283.

    Not in our library10.1016/j.neurobiolaging.2010.04.007

  119. 119.

    Sakamoto K. Matsuki S. Matsuguma K. Yoshihara T. Uchida N. Azuma F. (2017 ). BACE1 inhibitor lanabecestat (AZD3293) in a Phase 1 study of healthy Japanese subjects: pharmacokinetics and effects on plasma and cerebrospinal fluid Aβ peptides. J. Clin. Pharmacol. 57 1460–1471.

    Not in our library10.1002/jcph.950

  120. 120.

    Sano Y. Morishima-Kawashima M. Funamoto S. Ihara Y. Nagashima Y. Ishihara S. (2009 ). γ-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of -Carboxyl terminal fragment. J. Neurosci. 29 13042–13052.

    Not in our library10.1523/jneurosci.2362-09.2009

  121. 121.

    Saura C. A. Choi S. Y. Beglopoulos V. Malkani S. Zhang D. Rao B. S. S. (2004 ). Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42 23–36.

    Not in our library10.1016/s0896-6273(04)00182-5

  122. 122.

    Scott J. D. Li S. W. Brunskill A. P. J. Chen X. Cox K. Cumming J. N. (2016 ). Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-A β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer’s disease. J. Med. Chem. 59 10435–10450.

    Not in our library10.1021/acs.jmedchem.6b00307

  123. 123.

    Selkoe D. J. (2001 ). Alzheimer’s disease: genes, proteins, and therapy. Perspective 81 741–767.

    Not in our library10.1152/physrev.2001.81.2.741

  124. 124.

    Selkoe D. J. Hardy J. Sciences B. Hu N.-W. Nicoll A. J. Zhang D. (2016 ). Amyloid β-protein dimers isolated directly from Alzheimer brains impair synaptic plasticity and memory. Nat. Med. 7:3374

    Not in our library10.1038/nm1782.amyloid

  125. 125.

    Selkoe D. J. Wolfe M. S. (2007 ). Presenilin: running with scissors in the membrane. Cell 131 215–221.

    Not in our library10.1016/j.cell.2007.10.012

  126. 126.

    Shah S. Lee S. F. Tabuchi K. Hao Y. H. Yu C. LaPlant Q. (2005 ). Nicastrin functions as a γ-secretase-substrate receptor. Cell 122 435–447.

    Not in our library10.1016/j.cell.2005.05.022

  127. 127.

    Shan W. J. Huang L. Zhou Q. Meng F. C. Li X. S. (2011 ). Synthesis, biological evaluation of 9-N-substituted berberine derivatives as multi-functional agents of antioxidant, inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation. Eur. J. Med. Chem. 46 5885–5893.

    Not in our library10.1016/j.ejmech.2011.09.051

  128. 128.

    Shearman M. S. Beher D. Clarke E. E. Lewis H. D. Harrison T. Hunt P. (2000 ). L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry 39 8698–8704.

    Not in our library10.1021/bi0005456

  129. 129.

    Shuto D. Kasai S. Kimura T. Liu P. Hidaka K. Hamada T. (2003 ). KMI-008, a novel β-Secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorganic Med. Chem. Lett. 13 4273–4276.

    Not in our library10.1016/j.bmcl.2003.09.053

  130. 130.

    Sims J. R. Selzler K. J. Downing A. M. Willis B. A. Aluise C. D. Zimmer J. (2017 ). Development review of the BACE1 inhibitor lanabecestat (AZD3293/LY3314814). J. Prev. Alzheimer’s Dis. 4 247–254.

    Not in our library10.14283/jpad.2017.38

  131. 131.

    Sisodia S. S. (1992 ). Secretion of the β−amyloid precursor protein. Ann. N. Y. Acad. Sci. 674 53–57.

    Not in our library10.1111/j.1749-6632.1992.tb27476

  132. 132.
    Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism · 2014
    No notice
  133. 133.

    Sun Z. Y. Asberom T. Bara T. Bennett C. Burnett D. Chu I. (2012 ). Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo. J. Med. Chem. 55 489–502.

    Not in our library10.1021/jm201407j

  134. 134.

    Sverdlov O. Berman R. M. Castaneda L. Li H. Albright C. F. Wong O. (2012 ). Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin. Ther. 34 654–667.

    Not in our library10.1016/j.clinthera.2012.01.022

  135. 135.

    Szaruga M. Munteanu B. Lismont S. Veugelen S. Horré K. Mercken M. (2017 ). Alzheimer’s-causing mutations shift Aβ length by Destabilizing γ-secretase-Aβn interactions. Cell 170:443–456.e14.

    Not in our library10.1016/j.cell.2017.07.004

  136. 136.

    Tagami S. Yanagida K. Kodama T. S. Takami M. Mizuta N. Oyama H. (2017 ). Semagacestat is a pseudo-inhibitor of γ-secretase. Cell Rep. 21 259–273.

    Not in our library10.1016/j.celrep.2017.09.032

  137. 137.

    Takasugi N. Tomita T. Hayashi I. Tsuruoka M. Niimura M. Takahashi Y. (2003 ). The role of presenilin cofactors in the gamma-secretase complex. Nature 422 438–441.

    Not in our library10.1038/nature01506

  138. 138.

    Takeo K. Tanimura S. Shinoda T. Osawa S. Zahariev I. K. Takegami N. (2014 ). Allosteric regulation of -secretase activity by a phenylimidazole-type -secretase modulator. Proc. Natl. Acad. Sci. U.S.A. 111 10544–10549.

    Not in our library10.1073/pnas.1402171111

  139. 139.

    Thijssen E. H. La Joie R. Wolf A. Strom A. Wang P. Iaccarino L. (2020 ). Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat. Med. 26 387–397.

    Not in our library10.1038/s41591-020-0762-2

  140. 140.

    Thinakaran G. Borchelt D. R. Lee M. K. Slunt H. H. Spitzer L. Kim G. (1996 ). Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17 181–190.

    Not in our library10.1016/s0896-6273(00)80291-3

  141. 141.

    Thinakaran G. Koo E. H. (2008 ). Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283 29615–29619.

    Not in our library10.1074/jbc.r800019200

  142. 142.

    Timmers M. Streffer J. R. Russu A. Tominaga Y. Shimizu H. Shiraishi A. (2018 ). Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study. Alzheimer’s Res. Ther. 10 1–18.

    Not in our library10.1186/s13195-018-0415-6

  143. 143.

    Timmers M. Van Broeck B. Ramael S. Slemmon J. De Waepenaert K. Russu A. (2016 ). Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimer’s Dement. Transl. Res. Clin. Interv. 2 202–212.

    Not in our library10.1016/j.trci.2016.08.001

  144. 144.

    Ufer M. Rouzade-Dominguez M.-L. Huledal G. Pezous N. Avrameas A. David O. (2016 ). Results from a first-in-human study with the bace inhibitor Cnp520. Alzheimer’s Dement. 12:200

    Not in our library10.1016/j.jalz.2016.06.351

  145. 145.

    van Dyck C. H. Brody M. Salloway S. Rollin L. Pilcher G. Berman R. M. (2012 ). Safety and tolerability of the γ-secretase inhibitor avagacestat in a Phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol. 69:1430.

    Not in our library10.1001/archneurol.2012.2194

  146. 146.

    Vassar R. (2004 ). The β-secretase enzyme in Alzheimer’s disease. Mol. Biol. 23 105–113.

    Not in our library10.1385/jmn:23:1-2:105

  147. 147.

    Vassar R. Bennett B. D. Babu-Khan S. Kahn S. Mendiaz E. A. Rogers G. (1999 ). β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 735–741.

    Not in our library10.1126/science.286.5440.735

  148. 148.

    Veugelen S. Saito T. Saido T. C. Chávez-Gutiérrez L. De Strooper B. (2016 ). Familial Alzheimer’s disease mutations in presenilin generate amyloidogenic Aβ peptide seeds. Neuron 90 410–416.

    Not in our library10.1016/j.neuron.2016.03.010

  149. 149.

    Wang H. Wang H. Cheng H. Che Z. (2016 ). Ameliorating effect of luteolin on memory impairment in an Alzheimer’s disease model. Mol. Med. Rep. 13 4215–4220.

    Not in our library10.3892/mmr.2016.5052

  150. 150.

    Watanabe H. Xia D. Kanekiyo T. Kelleher R. J. Shen J. (2012 ). Familial frontotemporal dementia-associated presenilin-1 c.548G>T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice. J. Neurosci. 32 5085–5096.

    Not in our library10.1523/jneurosci.0317-12.2012

  151. 151.

    Weggen S. Eriksen J. L. Das P. Sagi S. A. Wang R. Pietrzik C. U. (2001 ). A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414 212–216.

    Not in our library10.1038/35102591

  152. 152.

    Wilcox K. C. Lacor P. N. Pitt J. Klein W. L. (2011 ). Aβ oligomer-induced synapse degeneration in Alzheimer’s disease. Cell. Mol. Neurobiol. 31 939–948.

    Not in our library10.1007/s10571-011-9691-4

  153. 153.

    Wildsmith K. R. Holley M. Savage J. C. Skerrett R. Landreth G. E. (2013 ). Evidence for impaired amyloid β clearance in Alzheimer’s disease. Alzheimer’s Res. Ther. 5:33.

    Not in our library10.1186/alzrt187

  154. 154.

    Willis B. A. Lowe S. L. Daugherty L. L. Dean R. A. English B. Ereshefsky L. (2016 ). Pharmacokinetics, pharmacodynamics, safety, and tolerability of Ly3202626, a novel Bace1 inhibitor, in healthy subjects and patients with Alzheimer’S disease. Alzheimer’s Dement. 12:418

    Not in our library10.1016/j.jalz.2016.06.791

  155. 155.

    Wilson C. A. Doms R. W. Lee V. M. Y. (1999 ). Intracellular APP processing and Aβ production in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58 787–794.

    Not in our library10.1097/00005072-199908000-00001

  156. 156.

    Wimo A. Winblad B. Jönsson L. (2010 ). The worldwide societal costs of dementia: estimates for 2009. Alzheimer’s Dement. 6 98–103.

    Not in our library10.1016/j.jalz.2010.01.010

  157. 157.
    Characterization of age-dependent and progressive cortical neuronal degeneration in presenilin conditional mutant mice. · 2010
    Not checked
  158. 158.

    Wolfe M. S. (2006 ). The γ-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45 7931–7939.

    Not in our library10.1021/bi060799c

  159. 159.

    Wolfe M. S. Kopan R. (2004 ). Intramembrane proteolysis: theme and variations. Science 305 1119–1123.

    Not in our library10.1126/science.1096187

  160. 160.

    Wolfe M. S. Xia W. Ostaszewski B. L. Diehl T. S. Kimberly W. T. Selkoe D. J. (1999 ). Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398 513–517.

    Not in our library10.1038/19077

  161. 161.

    Xiong C. Jasielec M. S. Weng H. Fagan A. M. Benzinger T. L. S. Head D. (2016 ). Longitudinal relationships among biomarkers for Alzheimer disease in the adult children study. Neurology 86 1499–1506.

    Not in our library10.1212/wnl.0000000000002593

  162. 162.

    Yan R. Blenkowski M. J. Shuck M. E. Miao H. Tory M. C. Pauley A. M. (1999 ). Membrane-anchored aspartyl protease with Alzheimer’s disease β- secretase activity. Nature 402 533–537.

    Not in our library10.1038/990107

  163. 163.

    Yang G. Zhou R. Zhou Q. Guo X. Yan C. Ke M. (2019 ). Structural basis of Notch recognition by human γ-secretase. Nature 565 192–197.

    Not in our library10.1038/s41586-018-0813-8

  164. 164.
    A data-driven model of biomarker changes in sporadic Alzheimer's disease · 2014
    No notice
  165. 165.

    Zhao J. Xiao Y. Liu X. Kim S. Wu X. Barros M. (2020 ). Substrate interaction inhibits γ-secretase production of amyloid-β peptides. Chem. Commun. 56 2578–2581.

    Not in our library10.1039/c9cc09170j

  166. 166.

    Zhou R. Yang G. Guo X. Zhou Q. Lei J. Shi Y. (2019 ). Recognition of the amyloid precursor protein by human g-secretase. Science 363:eaaw0930.

    Not in our library10.1126/science.aaw0930

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.